M Ian Phillips
Overview
Explore the profile of M Ian Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burns A, Doris C, Vehar K, Saxena V, Bardliving C, Shamlou P, et al.
PLoS One
. 2021 Jun;
16(6):e0252575.
PMID: 34133442
Bone marrow derived human Mesenchymal Stem Cells (hMSCs) are an attractive candidate for regenerative medicine. However, their harvest can be invasive, painful, and expensive, making it difficult to supply the...
2.
Fernandes T, Barretti D, Phillips M, Oliveira E
Mol Cell Endocrinol
. 2018 May;
476:148-154.
PMID: 29746886
Exercise training (ET) has been established as an important treatment for obesity, since it counteracts aberrant cardiac metabolism and weight gain; however, underlying mechanisms remain to be further determined. MicroRNAs...
3.
Phillips M, Costales J, Lee R, Oliveira E, Burns A
Curr Pharm Des
. 2015 Aug;
21(30):4417-26.
PMID: 26234793
Antisense oligonucleotide therapy is a growing field in cardiac, metabolic, and muscular diseases. This precision therapy allows for treatment of diseases due to specific genetic defects. Antisense has few side...
4.
Fernandes T, Barauna V, Negrao C, Phillips M, Oliveira E
Am J Physiol Heart Circ Physiol
. 2015 Jun;
309(4):H543-52.
PMID: 26071549
Left ventricular (LV) hypertrophy is an important physiological compensatory mechanism in response to chronic increase in hemodynamic overload. There are two different forms of LV hypertrophy, one physiological and another...
5.
Chen L, Phillips M, Miao H, Zeng R, Qin G, Kim I, et al.
PLoS One
. 2014 Oct;
9(10):e107841.
PMID: 25357000
Stem cell therapy has a potential for regenerating damaged myocardium. However, a key obstacle to cell therapy's success is the loss of engrafted cells due to apoptosis or necrosis in...
6.
7.
Tang D, Shun L, Koya V, Sun Y, Wang Q, Wang H, et al.
Am J Transl Res
. 2013 Apr;
5(2):184-99.
PMID: 23573363
Many previous studies demonstrate that hepatocytes can be reprogrammed into insulin-producing cells (IPCs) utilizing viral vector-mediated delivery of pancreatic transcription factors (PTFs). However, whether these liver-derived IPCs are susceptible to...
8.
Phillips M, Tang Y
Prog Mol Biol Transl Sci
. 2012 Aug;
111:285-304.
PMID: 22917236
Gene modification of stem cells prior to their transplantation enhances their survival and increases their function in cell therapy. Like the famous Trojan horse, the gene-modified cell has to gain...
9.
Phillips M
Clin Pharmacol Ther
. 2012 Jun;
92(2):182-92.
PMID: 22739143
There are an estimated 7,000 "orphan diseases," but treatments are currently available for only about 5% of them. Recent progress in the advanced platforms of gene therapy, stem cell therapy,...
10.
Thorat C, Xu K, Freeman S, Bonnel R, Joseph F, Phillips M, et al.
Pediatrics
. 2012 Feb;
129(3):516-21.
PMID: 22371464
Objectives: The 1983 US Orphan Drug Act (ODA) provided incentives to stimulate treatment product development for patients with rare disease. This article highlights a decade of ODA contributions to this...